Role of cytokines in myocardial ischemia and reperfusion

Mediators of Inflammation

Volumn 6, Issue 3, 1997, Pages 175-183

  Sharma, H S ^a   Das, D K ^b  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Cytokine; Heart; IL 1; IL 6; Ischemia reperfusion; TGF ; TNF

Indexed keywords

ANGIOGENIC FACTOR; CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADAPTATION; CELL PROTECTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HUMAN; HYPOXIA; INFLAMMATION; MEDIATOR; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0030877145     PISSN: 09629351     EISSN: None     Source Type: Journal    
DOI: 10.1080/09629359791668     Document Type: Review

References (109)

1. Jennings R, Schaper J, Hill M, Steenbergen C, Reimer K. Effect of reperfusion late in the phase of reversible ischemic injury. Circ Res 1985; 56: 262-271.
2. Jennings RB, Sommer HM. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch Pathol 1960; 70: 68-81.
3. Bolli R. Mechanisms of myocardial stunning. Circulation 1990; 82: 723-738.
4. Kusuoka H, Marban E. Cellular mechanisms of myocardial stunning. Annu Rev Physiol 1992; 54: 243-256.
5. Murry CE, Richard VJ, Reimer KA, Jennings RB. Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode. Circ Res 1990; 66: 913-931.
6. Schott R, Rohmann S, Braun E, Schaper W. Ischemic preconditioning reduces infarct size in swine myocardium. Circ Res 1990; 66: 1133-1142.
7. Sharma HS, Wünsch M, Brand T, Verdouw PD, Schaper W. Molecular biology of the coronary vascular and myocardial responses to ischemia. J Cardiovasc Pharmacol 1992; 20: S23-S31.
8. Görge G, Schmidt T, Ito BR, Pantely GA, Schaper W. Microvascular and collateral adaptation in swine hearts following progressive coronary artery stenosis. Basic Res Cardiol 1989; 84: 524-535.
9. Schaper W, Schaper J. Adaptation to and defense against myocardial ischemia. Cardiol 1990; 77: 367-372.
10. Andres J, Sharma HS, Knöll R, et al. Expression of heat shock proteins in the normal and stunned porcine myocardium. Cardiovas Res 1993; 27: 1421-1429
11. Brand T, Sharma HS, Fleischmann KE, et al. Proto-oncogene expression in porcine myocardium subjected to ischemia and reperfusion. Circ Res 1992; 71: 1351-1360.
12. Sharma HS, Maulik N, Gho BC, Das DK, Verdouw PD. Coordinated expression of heme oxygenase-1 and ubiquitin in the porcine heart subjected to ischemia and reperfusion. Mol Cell Biochem 1996; 157: 111-116.
13. Frass O, Sharma HS, Fleischmann K, et al. Enhanced gene expression of calcium regulatory proteins in porcine stunned myocardium. Cardiovas Res 1993; 27: 2037-2043.
14. Sharma HS, Verdouw PD, Lamers JMJ. Involvement of sarcoplasmic reticulum calcium pump in myocardial contractile dysfunction: Comparison between chronic pressure-overload and stunning. Cardiovas Drugs Ther 1994; 8: 461-468.
15. Sharma HS, Zimmermann R. Growth Factors and development of coronary collaterals. In: Cummins P ed. Growth Factors and the Cardiovascular System. Kluwer Academic Publishers, 1993: 119-148.
16. Sharma HS, Tang ZH, Tang, Gho BC, Sassen LMA, Vedouw PD. Expression and immunohistochemical localization of vascular endothelial growth factor during ischemia induced ventricular dysfunction in pigs. Circulation 1994; 90: 15-22.
17. Johnson PFL. Eukaryotic transcriptional regulatory proteins. Ann Rev Biochem 1989; 58: 799-839.
18. Zelenka PS. Proto-oncogenes in cell differentiation. Bio-Essays 1990; 12: 22-26.
19. Welch W. Mammalian stress response: cell physiology, structure/ function of stress proteins, and implications for medicine and disease. Physiological Reviews 1992, 72: 1063-1081.
20. Yellon D, Latchman D. Stress proteins and myocardial protection. J Mol Cell Cardiol 1992; 24: 113-124.
21. Sharma HS, Snoeckx LH, Sassen LMA, et al. Expression and immunohistochemical localization of heat shock protein-70 in preconditioned porcine myocardium. Annals New York Acad Sci 1994; 723: 491-494.
22. Sharma HS, Stahl J. Role of small heat shock proteins in the cardiovascular system. In: Knowlton AA, ed. Heat Shock Proteins and the Cardiovascular System. Boston: Kluwer Academic Publishers 1997.
23. Sharma HS, Stahl J, Weisensee D, Löw-Friedrich I. Cytoprotective mechanisms in cardiomyocytes. Mol Cell Biochem 1996; 160/161: 217-224.
24. Ciocca DR, Oesterreich S, Chamness GC, McGuire WL, Fuqua SA. Biological and clinical implications of heat shock protein 27,000 (Hsp27): a review. J Natl Cancer Inst 1993; 85: 1558-1570.
25. Knowlton AA. The role of heat shock proteins in the heart. J Mol Cell Cardiol 1995; 27: 121-131.
26. Knowlton A, Brecher P, Apstein C, Ngoy S, Romo G. Rapid expression of heat shock protein in the rabbit after brief cardiac ischemia. J Clin Invest 1991; 87: 139-147.
27. Heads RJ, Yellon DM, Latchman DS. Differential cytoprotection against heat stress or hypoxia following expression of specific stress protein genes in myogenic cells. J Mol Cell Cardiol 1995; 27: 1669-1678.
28. Mestril R, Dillmann WH. Heat shock proteins and protection against myocardial ischemia. J Mol Cell Cardiol 1995; 27: 45-52.
29. Hayashi T, Takada K, Matsuda M. Post-transient ischemia increase in ubiquitin conjugates in the early reperfusion. NeuroReport 1992; 3: 519-520.
30. Hershko A, Ciechanover A. The ubiquitin system for protein degradation. Annu Rev Biochem 1992; 61: 761-807.
31. Jentsch S. Ubiquitin-dependent protein degradation: a cellular perspective. Trends in Cell Biology 1992; 2: 98-103.
32. Das DK, Engelman RM, Kimura Y. Molecular adaptation of cellular defences following preconditioning of the heart by repeated ischemia. Cardiovas Res 1993; 27: 578-584.
33. Maulik N, Sharma HS, Das DK. Induction of heme oxygenage gene expression during the reperfusion of ischemic rat myocardium. J Mol Cell Cardiol 1996; 28: 1261-1270.
34. Thompson NL, Basoberry F, Spier EH, et al. TGF-β1 in acute myocardial infarction in rats. Growth Factor 1988; 1: 91-99.
35. Eghbali M. Cellular origin and distribution of transforming growth factor β in the normal rat myocardium. Cell Tissue Res 1989; 256: 553-558.
36. Wünsch M, Sharma HS, Markert T, et al. In situ localization of transforming growth factor-β1 in porcine heart: Enhanced expression after chronic coronary artery constriction J Mol Cell Cardiol 1991; 23: 1051-1062.
37. Roberts AB, Sporn MB, Assoian, RK, et al. TGF-β: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci (USA) 1986; 83: 4167-4171.
38. Mustoe TA, Pierce GF, Thomason A, Gramates P, Sporn MB, Deuel TF. Accelerated healing of incisional wounds in rats induced by transforming growth factor-beta. Science 1987; 237: 1333-1336.
39. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931-10934.
40. Lefer AM. Mechanism of the protective effects of transforming growth factor-β in reperfusion injury. Biochem Pharmacol 1991; 42: 1323-1327.
41. Lefer AM, Tsao P, Aoki N, Palladino MJ. Mediation of cardioprotection by transforming growth factor-β. Science 1990; 249: 61-64.
42. MacLellan WR, Brand T, Schneider MD. Transforming growth factor-beta in cardiac ontogeny and adaptation. Circ Res 1993; 73: 783-791.
43. Roberts AB, Sporn MB. Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta). Growth Factors 1993; 8: 1-9.
44. Tracey KJ, Cerami A. Tumor necrosis factor: A pleiotropic cytokine and therapeutic target. Ann Rev Med 1994; 45: 491-503.
45. Sherry B, Cerami A. Cachetin/tumor necrosis factor exerts endocrine, paracrine, and autocrine control of inflammatory responses. J Cell Biol 1988; 107: 1269-1277.
46. Ikeda U, Ikeda M, Kano S, Shimada K. Neutrophil adherence to rat cardiac myocyte by proinflammatory cytokines. J Cardiovas Pharmacol 1994; 23: 647-652.
47. Sharma HS, Weisensee D, Löw-Friedrich I, Schoeppe W, Schaper W. Vascular endothelial growth factor expression in cardiac myocytes in vitro and its upregulation by tumor necrosis factor-α. J Cell Biochem 1993; 17D: 216.
48. Tartaglia LA, Weber RF, Figari IS, Reynolds C, Palladino MJ, Goeddel DV. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci (USA) 1991; 88: 9292-9296.
49. Wiegmann K, Schutze S, Kampen E, Himmler A, Machleidt T, Kronke M. Human 55-kDa receptor for tumor necrosis factor coupled to signal transduction cascades. J Biol Chem 1992; 267: 17997-18001.
50. Heller RA, Kronke M. Tumor necrosis factor receptor-mediated signaling pathways. J Cell Biol 1994; 126: 5-12.
51. Rothe J, Gehr G, Loetscher H, Lesslauer W. Tumor necrosis factor receptors- structure and function. Immunol Res 1992; 11: 81-90.
52. Vaddi K, Nicolini FA, Mehta P, Mehta JL. Increased secretion of tumor necrosis factor-alpha and interferon-gamma by mononuclear leukocytes in patients with ischemic heart disease. Relevance in superoxide anion generation. Circulation 1994; 90: 694-699.
53. Torre AG, Kapadia S, Lee J, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996; 93: 704-711.
54. Herskowitz A, Choi S, Ansari AA, Wesselingh S. Cytokine mRNA expression in postischemic/reperfused myocardium. Am J Pathol 1995; 146: 419-428.
55. Maury CP, Tempo AM. Circulating tumor necrosis factor-α (cachectin) in myocardial infarction. Am J Pathol 1989; 139: 709-715.
56. Eddy LJ, Goeddel DV, Wong GH. Tumor necrosis factor-α pretreatment is protective in a rat model of myocardial ischemia-reperfusion injury. Biochem Biophys Res Comm 1992; 184: 1056-1059.
57. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest 1993; 92: 2303-2312.
58. Low FI, Weisensee D, Mitrou V, Schoeppe W. Cytokines induce stress protein formation in cultured cardiac myocytes. Basic Res Cardiol 1992; 87: 12-18.
59. Kaur P, Welch WJ, Saklatvala J. Interleukin 1 and tumour necrosis factor increase phosphorylation of the small heat shock protein. Effects in firbroblasts, Hep G2 and U937 cells. FEBS Lett 1989; 258: 269-273.
60. Mehlen F, Mehlen A, Guillet D, Preville X, Arrigo AP. Tumor necrosis factor-α induces changes in the phosphorylation, cellular localization, and oligomerization of human hsp27, a stress protein that confers cellular resistance to this cytokine. J Cell Biochem 1995; 58: 248-259.
61. 1 alpha and G beta proteins and adenylyl cyclase responsiveness in rat cardiomyocytes. Eur J Pharmacol 1991; 206: 53-60.
62. Engel K, Ahlers A, Brach MA, Herrmann F, Gaestel M. MAPKAP Kinase 2 is activated by heat shock and TNF-α: In vivo phosphorylation of small heat shock protein results from stimulation of the MAP Kinase cascade. J Cell Biochem 1995; 57: 321-330.
63. Weisensee D, Bereiter HJ, Schoeppe W, Low FI. Effects of cytokines on the contractility of cultured cardiac myocytes. Int J Immunopharmacol 1993; 15: 581-587.
64. Sharma HS, Weisensee D, Low FI. Tumor necrosis factor-alpha-induced cytoprotective mechanisms in cardiomyocytes. Analysis by mRNA phenotyping. Ann N Y Acad Sci 1996; 793: 267-281.
65. Lord PCW, Wilmoth LMG, Mizel SB, McCall CE. Expression of interleukin-1α and β genes by human blood polymorphonuclear leukocytes. J Clin Invest 1991; 87: 1312-1321.
66. Dinarello CA. Biology of interleukin I. FASEB J 1988; 2: 108-115.
67. Akira S, Hirano T, Taga T, Kishimoto T. Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J 1990; 4: 2860-2867.
68. Kilian PL, Kaffka KL, Stern AS, et al. Interleukin-1α and interleukin-1β bind to the same receptor on T cells. J Immunol 1986; 136: 4509-4514.
69. Whither JT, Evans SW. Cytokines in disease. Clin Chem 1990; 36/7: 1269-1281.
70. Rubartelli A, Cozzolino F, Talio M, Sitia R. A novel secretory pathway for interleukin-1β, a protein lacking a signal sequence. EMBO J 1990; 9: 1503-1510.
71. Okusawa S, Gelfand JA, Ikejima T, Connoly RJ, Dinarello CA. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 1988; 81: 1162-1172.
72. Loppnow H, Libby P. Proliferating interleukin 1 activated human vascular smooth muscle cells secrete copius interleukin 6. J Clin Invest 1990; 85: 731-738.
73. Han RO, Ray PE, Baughman KL, Feldman AM. Detection of interleukin and interleukin-receptor mRNA in human heart by polymerase chain reaction. Biochem Biophys Res Comm 1991; 181: 520-523.
74. Tsujino M, Hirata Y, Imai T, et al. Induction of nitric oxide synthase gene by interleukin-1β in cultured rat cardiomyocytes. Circulation 1994; 90: 375-383.
75. Nogae C, Makino N, Hata T, et al. Interleukin 1 alpha-induced expression of manganous superoxide dismutase reduces myocardial reperfusion injury in the rat. J Mol Cell Cardiol 1995; 27: 2091-2099.
76. Bendtzen K. Interleukin 1, interleukin 6 and tumor necrosis factor in infection, inflammation and immunity. Immunol Lett 1988; 19: 183-192.
77. Hennein HA, Ebba H, Rodriguez JL, et al. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J Thorac Cardiovasc Surg 1994; 108: 626-635.
78. Hirano T, Yasukawa K, Harada H, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986; 324: 73-76.
79. Geiger T, Andus T, Klapproth J, Hirano T, Kishimoto T, Heinrich PC. Induction of acute phase-proteins by interleukin 6 in vivo. Eur J Immunol 1988; 18: 717-721.
80. Morimoto S, Nabata T, Koh E, et al. Interleukin-6 stimulates proliferation of cultured vascular smooth muscle cells independently of interleukin-1β. J Cardiovas Pharmacol 1991; 17 (suppl. 2): S117-S118.
81. Yamauchi TK, Ihara Y, Ogata A, Yoshizaki K, Azuma J, Kishimoto T. Hypoxic stress induces cardiac myocyte-derived interleukin-6. Circulation 1995; 91: 1520-1524.
82. Ikeda U, Ohkawa F, Seino Y, et al. Serum interleukin 6 levels become elevated in acute myocardial infarction. J Mol Cell Cardiol 1992; 24: 579-584.
83. Kukielka GL, Youker KA, Hawkins HK, et al. Regulation of ICAM-1 and IL-6 in myocardial ischemia: effect of reperfusion. Ann N Y Acad Sci 1994; 723: 258-270.
84. Haeffner-Cavaillon N, Roussellier N, Ponzio O, et al. Induction of interleukin-1 production in patients undergoing cardiopulmonary bypass. J Thorac Cardiopulmo Surg 1989; 98: 1100-1106.
85. Finkel MS, Hoffman RA, Shen L, Oddis CV, Simmons RL, Hattler BG. Interleukin-6 as a mediator of stunned myocardium. Am J Cardiol 1993; 71: 1231-1232.
86. Kalfin RE, Engelman RM, Rousou JA, et al. Induction of interleukin-8 expression during cardiopulmonary bypass. Circulation 1993; 88: 401-406.
87. Kruse-Elliott KT, Olson NC. CGS 8515 and indomethacin attenuate cytokine-induced cardiopulmonary disfunction in pigs. Am J Physiol 1993; 264: H1075-H1086.
88. Walsh CJ, Sugerman HJ, Mullen PG, et al. Monoclonal antibody to tumor necrosis factor α attenuates cardiopulmonary dysfunction in porcine Gram-negative sepsis. Arch Surg 1992; 127: 138-145.
89. Fosse E, Mollnes TE, Ingvaldsen B. Complement activation during major operations with or without cardiopulmonary bypass. J Thoracic Cardiovasc Surg 1987; 93: 860-866.
90. Hind CRK, Griffin JE Pack F, et al. Effect of cardiopulmonary bypass on circulating concentrations of leukocyte elastase and free radical activity. Cardiovasc Res 1988; 22: 37-41.
91. Das DK, Engelman RM. Mechanisms of free radical generation in ischemic and reperfused myocardium In: Das DK, Essman WB eds. Oxygen Radicals: Systemic Events and Disease Processes. Basel: Krager, 1990: 97-128.
92. Chenoweth DE, Cooper SW, Hugli TE, Stewart RW, Blackstone EH, Kirklin JW. Complement activation during cardiopulmonary bypass. N Engl J Med 1981; 304: 497-503.
93. Nilsson L, Brunnkvist S, Nilsson T, et al. Activation of inflammatory systems during cardiopulmonay bypass. Scand J Thorac Cardiovasc Surg 1988; 22: 51-53.
94. Lucchesi BR, Mullane KM. Leukocytes and ischemia induced myocardial injury. Ann Rev Pharmacol Toxicol 1986; 26: 201-224.
95. Thelen M, Peveri P, Kernen P, Tsharner VV, Walz A, Baggiolini M. Mechanism of neutrophil activation by NAF, a novel monocyte-derived peptide agonist. FASEB J 1988; 2: 2702-2706.
96. Bagchi D, Das DK, Engelman RM, Prasad MR, Subramanian R. Polymorphonuclear leucocytes as potential source of free radicals in the ischemic-reperfused myocardium. Eur Heart J 1990; 11: 800-813.
97. 2 activation and autoinduction of tumor necrosis factor gene expression by tumor necrosis factor. Cancer Res 1990; 50: 7101-7107.
98. Otani H, Engelman RM, Rousou JA, Breyer RH. Enhanced prostaglandin synthesis due to phospholipase breakdown in ischemic-reperfused myocardium. Control of its production by a phospholipase inhibitor or free radical scavengers. J Mol Cell Cardiol 1986; 18: 953-961.
99. Balligand JL, Ungureanu LD, Simmons WW, et al. Cytokine-inducible nitric oxide synthase (iNOS) expression in cardiac myocytes. Characterization and regulation of iNOS expression and detection of iNOS activity in single cardiac myocytes in vitro. J Biol Chem 1994; 269: 27580-27588.
100. Rozanski GJ, Witt RC. IL-1 inhibits β-adrenergic control of cardiac calcium current: role of L-arginine/nitric oxide pathway. Am J Physiol 1994; 267: H1753-H1758.
101. Engelman DT, Watanabe M, Engelman RM, et al. Constitutive nitric oxide release is impaired after ischemia and reperfusion. J Thorac Cardiovasc Surg 1995; 110: 1047-1053.
102. Evans HG, Lewis MJ, Shah AM. Interleukin 1β modulates myocardial contraction via dexamethasone sensitive production of nitric oxide. Cardiovasc Res 1993; 27: 1486-1490.
103. 2+-independent nitric oxide synthase in the myocardium. Br J Pharmacol 1992; 105: 575-580.
104. Maulik N, Watanabe M, Engelman DT, Engelman RM, Das DK. Oxidative stress adaptation improves postischemic ventricular recovery. Mol Cell Biochem 1995; 144: 67-74.
105. Ono M, Kohda H, Kawaguchi T, et al. Induction of Mn-superoxide dismutase by tumor necrosis factor, interleukin-1 and interleukin-6 in human hepatoma cells. Biochem Biophys Res Commun 1992; 182: 1110-1107.
106. Yamada M, Sohmura Y, Nakamura S, Hashimoto M. Interleukin-1α: its possible roles in cancer tharapy. Biotherapy 1989; 1: 327-338.
107. 125I-labeled IL-1α in a human large granular lymphocyte cell line. J Immunol 1986; 137: 3183-3188.
108. Das DK, Engelman RM, Rousou JA, Breyer RH, Otani H, Lemeshow S. Pathophysiology of superoxide radical as potential mediator of reperfusion injury in pig heart. Basic Res Cardiol 1986; 81: 155-166.
109. Maulik N, Engelman RM, Wei Z, Lu D, Rousou JA, Das DK. Interleukin-α preconditioning reduces myocardial ischemia reperfusion injury. Circulation 1993; 88: 387-394.